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Abstract
Background: Ethnic variations in breast cancer epidemiology and genetics have necessitated investigation of the spectra of
BRCA1 and BRCA2 mutations in different populations. Knowledge of BRCA mutations in Chinese populations is still largely
unknown. We conducted a multi-center study to characterize the spectra of BRCA mutations in Chinese breast and ovarian
cancer patients from Southern China.
Methodology/Principal Findings: A total of 651 clinically high-risk breast and/or ovarian cancer patients were recruited
from the Hong Kong Hereditary Breast Cancer Family Registry from 2007 to 2011. Comprehensive BRCA1 and BRCA2
mutation screening was performed using bi-directional sequencing of all coding exons of BRCA1 and BRCA2. Sequencing
results were confirmed by in-house developed full high resolution DNA melting (HRM) analysis. Among the 451 probands
analyzed, 69 (15.3%) deleterious BRCA mutations were identified, comprising 29 in BRCA1 and 40 in BRCA2. The four
recurrent BRCA1 mutations (c.470_471delCT, c.3342_3345delAGAA, c.5406+1_5406+3delGTA and c.981_982delAT)
accounted for 34.5% (10/29) of all BRCA1 mutations in this cohort. The four recurrent BRCA2 mutations
(c.2808_2811delACAA, c.3109C.T, c.7436_7805del370 and c.9097_9098insA) accounted for 40% (16/40) of all BRCA2
mutations. Haplotype analysis was performed to confirm 1 BRCA1 and 3 BRCA2 mutations are putative founder mutations.
Rapid HRM mutation screening for a panel of the founder mutations were developed and validated.
Conclusion: In this study, our findings suggest that BRCA mutations account for a substantial proportion of hereditary
breast/ovarian cancer in Southern Chinese population. Knowing the spectrum and frequency of the founder mutations in
this population will assist in the development of a cost-effective rapid screening assay, which in turn facilitates genetic
counseling and testing for the purpose of cancer risk assessment.
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Introduction
The incidence of breast cancer in Asia has rapidly increased
over the past 10 years and is one of the highest in Hong Kong
population [1]. Several reports have found differences in breast
cancer epidemiology between Asian and Caucasian populations,
probably due to interactions between different lifestyle and genetic
characteristics [2,3,4]. As the breast cancer genetic predisposition
is increasingly understood, it transpires that ethnic differences
exist. To date, studies of BRCA mutation spectrum in Chinese
populations are limited [5,6] and most of these studies were
performed in single institutions or a small number of medical
centers [7,8,9]. Some studies only focused on BRCA1 [10,11] and
most did not perform BRCA1/2 mutational screening using
conventional full gene sequencing [12,13]. Thus, comprehensive
BRCA1 and BRCA2 mutation screening is rarely reported. In
additional to BRCA mutation spectrum, identification of founder
mutations in various ethnic groups is also important to improve
genetic screening and cancer risk assessment because it makes a
more specific approach for molecular testing that targets the
founder allele possible, thus resulting in reduced cost of genetic
testing and faster turnaround time. The high frequency of founder
mutations in a given population provides a large patient cohort not
only for robust information regarding penetrance but also accurate
assessment of the effectiveness of preventive measures.
The Hong Kong Special Administrative Region of the People’s
Republic of China is an advantageous location to conduct such
studies related to hereditary cancers in the Chinese population
where 95% of the population is comprised of Chinese [14].
Moreover, the one child policy in Mainland China that started in
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1979 thus limiting the number of relatives available for genetic
studies within Mainland China, does not apply to Hong Kong
[15]. Previously, we reported the first Hong Kong multi-center
study that comprised of 119 breast cancer patients from this region
to screen for coding sequence changes in the BRCA1 and BRCA2
genes using conventional full gene DNA sequencing and identified
a recurrent mutation c.3109C.T [16]. Although sequencing
technology is still the gold standard method for mutation
detection, the development of alternative methods such as high
resolution DNA melting (HRM) for mutation scanning is
emerging. We here set out to determine the spectrum of BRCA1
and BRCA2 mutations in a group of 651 Chinese probands
(inclusive of the 119 probands) from Southern China using full
gene sequencing and full high resolution DNA melting (HRM)
analysis. Our results also prompted us to investigate the usefulness
of rapid HRM for screening of the BRCA1 and BRCA2 founder
mutations in Chinese population.
Materials and Methods
Ethics Statement
The study was performed in accordance with the Declaration of
Helsinki. Written informed consent was obtained from all
participants involved in this study. This study was approved by
the Institutional Review Board of the University of Hong Kong/
Hospital Authority West Cluster and other contributing hospitals,
Hong Kong.
Patients and Selection Criteria
A total of 651 clinically high-risk breast and/or ovarian cancer
patients (probands), referred to the Hong Kong Hereditary and
High Risk Breast Cancer Programme (www.HRBCP.org) from 1
March 2007 to 28 Feb 2011, were recruited. This group of 651
probands contained all 119 probands from our previous report
[16], in which the recurrent mutation c.3109C.T was identified.
The first set of 451 patients was analyzed by full gene sequencing
and HRM assays. Among the 451 patients, 24 patients were
selected to use for HRM blind validation. The remaining 200
patients were recruited for recurrent mutation HRM screening
only. Based on the lower incidence of breast cancer in Asia
cohorts, clinically high-risk female patients who were included in
this study were defined as those who: (1) had at least one first- or
second- degree relative with breast and/or ovarian cancer,
regardless of age; (2) were less than 50 years of age at diagnosis;
(3) had bilateral breast cancer; (4) had triple negative (TN) or
medullary type pathology; (5) had at least one relative with cancers
other than breast and ovarian cancer such as stomach and prostate
that are known to be related to BRCA mutations; or (6) they were
ovarian cancer patients with a family history of breast cancer. The
distribution of the 651 patients into the 6 categories was shown in
Table S1. A standard epidemiological questionnaire, including a
detailed family history, was administered to patients and medical
information, including pathology reports, was retrieved from the
patient’s medical records. Information from the epidemiological
questionnaire included age at breast cancer diagnosis, other
cancers diagnosed in the patient, and a family history of breast,
ovarian, and other cancers in first, second, and third degree
relatives. In addition, the following were categorized as having
been used or not used: alcohol; tobacco; contraceptive pills,
patches or injections; hormone replacement treatments; and
infertility medications. Women were also asked if they had ever
been pregnant and breast fed any child and if they were pre- or
post-menopausal. Eligible patients were offered BRCA counseling
and testing, and were consented for genetic testing and blood and
tumor collection. Patients who tested positive for a BRCA mutation
were asked to help recruit their first-degree relatives, who were
also offered testing. Written informed consent was obtained from
all participants involved in this study. This study was approved by
the Institutional Review Board of The University of Hong Kong/
Hospital Authority West Cluster and other contributing hospitals,
Hong Kong.
BRCA Mutation Screening by Conventional DNA
Sequencing
BRCA1 and BRCA2 mutation detection was performed on
genomic DNA extracted from peripheral blood samples using
Qiagen DNA Mini blood Kit (Qiagen, Hilden, Germany)
according to manufacturer instructions. Mutation analysis was
performed by direct DNA sequencing of all coding exons of
BRCA1 and BRCA2 and partial flanking intronic sequences. PCR
conditions and primer sequences are available upon request [16].
Bi-directional sequencing was performed using BigDye Termina-
tor v3.1 Cycle Sequencing Kit and analyzed on an ABI 3130xl
genetic analyzer (Applied Biosystems, Foster City, CA). Sequenc-
ing results were compared with the reference DNA sequences
using Variant Reporter software (Applied Biosystems) and then
reviewed manually. Computational analysis for potential cryptic
splice site mutation was performed using splice site prediction
programs such as NNSPLICE and ESEF finder when sequence
changes were identified. All mutation and sequence variants are
named according to the recommendations for the description of
sequence variants of Human Genome Variation Society (HGVS).
DNA sequencing was supplemented by multiplex ligation depen-
dent probe amplification (MLPA) to detect large deletions or
rearrangements [17]. However for the specific aim of validating
HRM only in this study, data from DNA sequencing only was
utilized.
High Resolution DNA Melting Analysis
To cover all exons of BRCA1 and BRCA2, 41 PCR reactions for
BRCA1 and 63 PCR reactions for BRCA2 were developed in our
HRM run per each patient sample. Thus, samples were amplified
in 384-well plates. LightCycler 480 High Resolution Master kit
(Roche, Penzberg, Germany) was used for HRM analysis in
patient samples in LightCycler 480 system (Roche). In brief, each
reaction was performed in a final volume of 10 ml containing
20 ng of DNA, 0.25 mM of each primer (forward or reverse) and
1x LightCycler 480 HRM Master mix (Roche). The PCR profile
was pre-activation at 95uC for 10 min, followed by 45 cycles of
95uC for 10 sec, a touchdown from 65–53uC for 30 sec at 2.5uC/
sec and 72uC for 20 sec. At the end of the PCR cycles, PCR
products was denatured at 95uC for 1 min and rapidly cooled to
40uC for 1 min. HRM analyses were performed from 60uC
through to 98uC at a temperature gradient of 1uC/sec, acquiring
25 data points per uC. Each sample was run in duplicates for
analysis. The analytical methods have been applied previously to
our mutation scanning [18]. All HRM primer sequences for
BRCA1 and BRCA2 genes were listed in Table S2.
Haplotype Analysis
Individuals with identical BRCA1 and BRCA2 germline muta-
tions from unrelated families were genotyped for allele sharing
indicative of a common ancestor. Thus, haplotype analysis was
conducted at 6 microsatellite polymorphic loci D17S791,
D17S855, D17S1323, D17S1322, D17S1335 and D17S1185 of
the BRCA1 gene and at 6 loci D13S289, D13S1699, D13S1698,
D13S171, D13S1695 and D13S260 of the BRCA2 gene. Primer
BRCA1/2 Founder Mutations in Southern Chinese
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Table 1. Spectrum of BRCA pathogenic mutations identified.
Gene Exon/Intron Mutation Detected AA Change
Mutation
Type
No. of
Case BIC Entries
BRCA1
IVS5 c.212+1G.T p.C64X SS 1 4
5 c.212+1G.A p.Phe46_Arg71del26 1 None
8 c.470_471delCT p.Ser157X FS 4 4
8 c.442_444delCAG p.Gln148del 1 None
11 c.959_960delGA p.Arg320MetfsX5 FS 1 None
11 c.981_982delAT p.Cys328X FS 2 7
11 c.1016delA p.K339RfsX2 FS 1 1
11 c.1877_1878insTAGT p.Val627SerfsX4 1 14
11 c.1961_1962insA p.Tyr655ValfsX18 FS 1 9
11 c.2338C.T p.Gln780X 1 36
11 c.2635G.T p.Glu879X NS 1 2
11 c.3214delC p.Leu1072X 1 None
11 c.3342_3345delAGAA p.Glu1115X 2 None
11 c.3858_3861delTGAG p.Ser1286ArgfsX20 FS 1 1
11 c.4049_4050insG p.Glu1352GfsX4 FS 1 None
11 c.4065_4068delTCAA p.Asn1355LysfsX10 FS 1 132
14 c.4372C.T p.Gln1458X NS 1 1
15 c.4656C.G p.Tyr1552X 1 None
16 c.4695_4696insA p.Ser1566IlefsX8 FS 1 None
16 c.4903G.T p.Glu1635X 1 None
17–20 c.4987_5277del291 p.M1663I IFD 1 None
19 c.5193+1G.C p.Trp1718SerfsX2 FS 1 None
22 c.5406+1_5406+3delGTA p.Asp1778GlyfsX27 FS 2 None
BRCA2
3 c.250C.T p.Gln84X 1 5
10 c.1261C.T p.Q421X NS 1 1
11 c.2595delA p.Glu866LysfsX8 FS 1 None
11 c.2808_2811delACAA p.Ala938ProfsX21 FS 2 128
11 c.3109C.T p.Q1037X NS 10 5
11 c.3202delG p.Val1068TyrfsX9 FS 1 None
11 c.3836delA p.Asn1279MetfsX5 FS 1 None
11 c.4121delA p.Lys1374ArgfsX14 FS 1 None
11 c.4563_4564delGT p.L1522GfsX6 FS 1 None
11 c.5164_5165delAG p.S1722YfsX4 FS 1 2
11 c.5218_5223delTTAAGT p.Leu1740_Ser1741del 1 None
11 c.5722_5723delCT p.L1908RfsX2 FS 1 42
11 c.5851_5854delAGTT p.S1951WfsX11 FS 1 11
11 c.6096_6097insT p.Ile2033TyrfsX16 FS 1 None
13 c.7007G.T p.Gly2313AlafsX31 FS 1 1
14 c.7409_7410insT p.Thr2471HisfsX4 FS 1 None
15–16 c.7436_7805del370 p.Asp2479GlyfsX46 FS 2 None
15 c.7467_68insT p.I2490YfsX7 NS 1 None
15 c.7471C.T p.Q2491X NS 1 1
17 c.7878G.A p.Trp2626X 1 None
17 c.7976+1G.A p.Ala2603_Arg2659del57 SS 1 1
18 c.8047_8054dupGCAAAAAC p.L2686EfsX10 FS 1 None
18 c.8066_8067delGT p.V2690FfsX2 FS 1 None
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sequences of all microsatellite polymorphic markers were listed in
Table S3. These markers were localized in a ,5 Mb region
encompassing BRCA1 on chromosome 17q21.2–17q21.31 and a
,2.5 Mb region encompassing BRCA2 on chromosome 13q12.3–
13q13.1. Fluorescently end-labeled primers were used to amplify
the microsatellite polymorphic regions. Size fractioning of PCR
products were performed on a 3130xl Genetic Analyzer (Applied
Biosystems) using the GeneScan 500 LIZ Size Standard and
analyzed using the GeneMapper v3.7 software (Applied Biosys-
tems). Haplotype estimations were performed using software
program PHASE.
Statistical Analysis
P values from x2 analyses describe any difference in BRCA
mutations carriers among all Chinese female patients. The
significance of age and BRCA status of patients was determined
by Wilcoxon test. Fisher’s exact test was used in the analysis of
categorical data where expected counts are less than 5. Linear-by-
Linear association was used in the analysis of ordinal data. SPSS
for Windows Release 16.0 (SPSS Inc, Chicago, USA) was used to
analyze the data; statistical significance and marginal statistical
significance were set at P,0.05 and P,0.1 respectively.
Results
Patient Characteristics
This study included 651 probands (616 female and 35 male),
comprised of 611 breast cancer patients,17 ovarian cancer patients
and the remaining 23 patients with both breast and ovarian
patients. The mean age at diagnosis of breast cancer was 43 years
old (range 18–82) and that of ovarian cancer was 43 years old
(range 19–64). All probands were from Chinese ancestry and over
90% were from Guangdong province of Southern China.
Identification of BRCA1 and BRCA2 Mutations Using Bi-
directional Sequencing
Extensive sequence analysis of all coding exons in BRCA1 and
BRCA2 of a total of 451 probands out of the 651 patients were
conducted. Based on our sequencing results, 69 (69/451, 15.3%)
deleterious BRCA gene mutations were identified. Of the 69
deleterious mutations, 29 (29/69, 42%) were in BRCA1 and 40
(40/69, 58%) in BRCA2. There was no significant difference in the
age of breast cancer diagnosis between BRCA carriers and non-
BRCA carriers (p=0.325, Wilcoxon test). Although the mean age
of breast cancer diagnosis of BRCA2 mutation carriers (mean age
45.7) are slightly higher than that of BRCA1 mutation carriers
(mean age 40.4), the difference was not significant (p=0.455,
Wilcoxon test). The spectra of all deleterious mutations identified
are illustrated in Table 1. Of the 69 deleterious mutations, we
identified 29 (42.0%) novel deleterious mutations that have not
been published in the Breast Information Core Database of
National Institute of Health (BIC) as shown in Table 1. Among the
29 novel mutations, 12 were in BRCA1 and 17 were in BRCA2.
Most of the novel deleterious mutations cause sequence frame-
shift, leading to early termination of translation for protein
products. In this study, we identified 4 recurrent BRCA1 mutations
(c.470_471delCT, c.3342_3345delAGAA,
c.5406+1_5406+3delGTA and c.981_982delAT) accounted for
34.5% (10/29) of all BRCA1 mutations and 4 recurrent BRCA2
mutations (c.2808_2811delACAA, c.3109C.T,
c.7436_7805del370 and c.9097_9098insA) accounted for 40%
(16/40) of all BRCA2 mutations. In addition, among our cohort of
the 33 male probands, 7 (7/33, 21.2%) deleterious mutations were
found. Intriguingly, all 7 male probands carried BRCA2 deleterious
mutations only.
Diagnostic Performance of In-house Developed Full HRM
for Screening of BRCA1 and BRCA2 Mutations
Apart from the development of full BRCA1 and BRCA2 gene
sequencing, we also developed full HRM assays for rapid
screening of BRCA1 and BRCA2 mutations. In our developed full
gene HRM assays, there are 38 BRCA1 and 63 BRCA2 HRM
reactions per patients were established. In order to validate the
testing performance of our in-house developed HRM assays, 8
probands with known BRCA1 deleterious mutations and 12
probands with known BRCA2 deleterious mutation from the 451
patients were analyzed. Those known BRCA mutations were
Table 1. Cont.
Gene Exon/Intron Mutation Detected AA Change
Mutation
Type
No. of
Case BIC Entries
19–20 c.8332_8632del301 p.Ile2778LysfsX13 FS 1 None
21 c.8633_8754del122 p.E2878GfsX5 FS 1 None
23 c.9097_9098insA p.Thr3033AsnfsX11 FS 2 24
25 c.9393delC p.Lys3132AsnfsX6 FS 1 None
27 c.10150C.T p.Arg3384X 1 None
Abbreviation: SS, Splice-site mutation; NS, Nonsense mutation; FS, Frame-shift mutation; IFD, In-frame deletion mutation. Recurrent mutations are highlighted in bold.
doi:10.1371/journal.pone.0043994.t001
Table 2. Comparisons between HRM screening and
sequencing of BRCA1 and BRCA2 genes.
BRCA1 BRCA2
Number of Amplicons per Patient 38 63
Number of Patients 24 24
Total Number of Reactions 912 1512
Types of Heterozygous Variants 12 16
False Positive (FP) 11 24
False Negative (FN) 0 0
True Positive (TP) 120 76
True Negative (TN) 781 1412
Sensitivity 100.0% 100.0%
Specificity 98.6% 98.3%
doi:10.1371/journal.pone.0043994.t002
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previously identified by our full gene sequencing. In this first
validation set, all 24 deleterious mutations and variants identified
by sequencing were also detected by our in-house developed
HRM assays. Thus, the detection rate for variant detection was
100% when compared to sequencing.
In the second blind validation set, a cohort of 24 breast cancer
patients from the 451 study patients was analyzed. Of all 24
patients, there were 2 patients with different BRCA1 deleterious
mutations and 2 patients with different BRCA2 deleterious
mutations. The detailed breakdown of all mutations and variants
in the 24 patients was shown in Table S4. The results of the
mutation sequencing were blinded to the operator until all samples
had been scored by HRM assays. A total of 912 BRCA1 and 1512
BRCA2 amplicons were analyzed (Table 2). All deleterious
mutations examined by sequencing were also detected by HRM.
However, the HRM false positive rates of BRCA1 and BRCA2 were
1.2% (11/912) and 1.6% (24/1512) respectively. The calculated
sensitivity and specificity for BRCA1 mutation and variant
detection was 100% and 98.6% respectively while the sensitivity
and specificity for BRCA2 mutation and variant detection was
100% and 98.3% respectively (Table 2).
Founder Mutations Confirmed by Haplotype Analysis
In this study, a total of 4 recurrent BRCA1 mutations
(c.470_471delCT, c.3342_3345delAGAA,
c.5406+1_5406+3delGTA and c.981_982delAT) and 4 recurrent
BRCA2 mutations (c.2808_2811delACAA, c.3109C.T,
c.7436_7805del370 and c.9097_9098insA) were identified in our
Chinese cohort (Table 1). To determine whether these recurrent
mutations have arisen from a common ancestor, haplotype
analysis was performed in unrelated families including 10 BRCA1
probands with 20 of their family members, 12 BRCA2 probands
with 27 of their family members and 50 unrelated Chinese
individuals without any BRCA mutations. For BRCA1 recurrent
mutations, the genotypes of all probands, family members and
unrelated controls were examined at 6 polymorphic markers (3 are
BRCA1 intragenic markers). For BRCA2, the genotypes of all cases
were examined at 6 polymorphic markers (Table S5). Haplotype
analysis for each recurrent mutation contained at least two
unrelated families in which at least one of them has available
family members. Our results revealed that except for the mutation
negative family members and the 50 unrelated controls, carriers
with the recurrent BRCA1 mutation (c.981_982delAT) and 3
recurrent BRCA2 mutations (c.3109C.T, c.7436_7805del370 and
c.9097_9098insA) shared the same haplotype suggesting that these
4 putative founder mutations are derived from a common ancestor
(Tables S5). For the previously confirmed BRCA2 mutation
(c.3109C.T) [16], 6 additional unrelated patients were identified
from this cohort. Together with previous patients identified, this
founder mutation (c.3109C.T) accounted for 25% (10/40) of all
BRCA2 mutations and so far is the highest proportion found in our
cohort. For the only BRCA1 founder mutation confirmed, it
accounted for 6.9% (2/29) all BRCA1 mutations in this cohort
while all the BRCA2 founder mutations accounted for 35% (14/40)
of all BRCA2 mutations. Characteristics of all 451 probands with
or without BRCA mutations were shown in Table 3. Based on this
data, probands with BRCA mutations have higher frequency of the
family history of ovarian cancer than those without BRCA
mutations. Furthermore, probands with BRCA mutations have
greater average number of family member with breast cancer than
those without BRCA mutations.
Development of Rapid HRM Screening Assays for
Founder Mutations
As some recurrent mutations were confirmed to be founder
mutations in the Southern China population, we then rapidly
developed HRM screening assays targeting each founder or
recurrent mutations so as to further screen our Chinese
population. Due to the 370 bp deletion, BRCA2 founder mutation
(c.7436_7805del370) is not easily detected by HRM. Thus, a panel
of 5 HRM assays for the remaining founders was developed
(Figure 1 and 2) and the primer sequences were listed in Table 4.
HRM screening assays were performed on an independent cohort
of 200 Chinese breast cancer patients. Our results indicated that
our developed HRM assays can rapidly detect one more patients
Table 3. Characteristics of all probands with BRCA1/2 recurrent/founder mutations, with other mutations and without mutation
(N= 451).
Patients with recurrent/founder
mutations Patients with other mutations Patients without mutations
No. of cases 17 42 392
Gender F = 13 F = 39 F = 366
M=4 M=3 M=26
Ethnicity GD=69% GD= 93.3% GD= 84.9%
(9/13, missing cases = 4) (28/30, missing cases = 12) (275/324, missing cases = 68)
Mean age at BC diagnosed All: 48 All: 43 All: 44
F: 45 F: 42 F: 43
M: 59 M: 57 M: 62
History of OC 3/13 6/39 7/366
Mean age at OC diagnosed 48 51 34
(Range: 46–50) (Range: 38–64) (Range: 19–49)
No. of family member with BC 22 50 180
Avg. number of family member
with BC in each proband
1.29 1.19 0.46
Abbreviations: F, Female; M, Male; GD, Guangdong; N/A, Not available; BC, Breast cancer; OC, Ovarian cancer;
doi:10.1371/journal.pone.0043994.t003
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carried BRCA2 founder mutation (c.3109C.T) from the 200
patients. Taken all together, the overall frequency of BRCA2
(c.3109C.T) founder mutation observed was 1.7% (11/651)
among 651 Chinese patients and accounted for 26.8% (11/41) of
all BRCA2 mutations in our Southern Chinese cohort. The total of
3 recurrent BRCA2 mutations then accounted for 36.6% (15/41)
of all BRCA2 mutations.
Discussion
In this study, we report the contributions of BRCA mutations to
high-risk families of Chinese population from Southern China.
Increasing cancer rates are of great concern to these Asian
countries because these countries often have limited health and
medical care resources and infrastructures to meet the needs of
these patients. Thus, it is important to obtain a better
understanding of the causes of breast cancer among Asians and
other populations so as to improve prevention and cancer risk
assessment efficiently worldwide. To our knowledge, this is one of
the larger Chinese cohort studies comprising of 651 probands and
comprehensive full BRCA1 and BRCA2 gene sequencing on 451
probands was employed for mutation screening analysis. Our
findings revealed that the proportion of BRCAmutation is15.3% in
a defined high risk group of Chinese population while Caucasian
cohorts are estimated to be 5–13% [19,20]. As there are variations
in selection criteria, such difference is difficult to be compared
whether significance is obtained between Chinese and Caucasian
populations.
Unlike the Caucasian population, we found that a relative
predominance of BRCA2 mutations (58%), similar to that reported
in some Asian studies [9,21,22,23]. This may be that breast cancer
biology in Chinese is different to that of the Western population.
The predominance of BRCA2 founder mutations in our cohort was
higher when compared to that of the BRCA1 founder mutations.
Of note, a similar pattern of a predominance of BRCA2 mutations
compared to BRCA1 was recently observed in a study of high-risk
Asian-Americans [24].
In this study, we identified 29 novel deleterious BRCA mutations
which have not been published in the BIC Database of NIH. This
proportion is relatively high in our Chinese cohort. Reports have
found a high frequency of variants in different ethnic populations
[8,11,25,26]. This is likely due to the limited knowledge of the
mutation spectrum in different ethnic populations where BRCA
testing have not be widely performed, especially in Chinese
population [27].
Notably, we discovered three BRCA1 and three BRCA2 putative
founder mutations in our Southern Chinese cohort. Interestingly,
we also observed that half of the putative founder mutations (3 of
6) have not been published in the BIC Database (Table 1). Since
there are only two cases reported for each of the novel putative
founder mutation (BRCA1 c.3342_3345delAGAA,
c.5406+1_5406+3delGTA and BRCA2 c.7436_7805del370), their
founder effects are required to be confirmed by larger sample size
of unrelated probands. The BRCA1 and BRCA2 recurring
mutations that did not share a common haplotype could also be
attributable to factors such as age of mutation such that associated
alleles are no longer in linkage disequilibrium with microsatellite
marker. Founder mutations not only provide population-specific
genetic risk assessment, but are also useful in the study of
penetrance of BRCA mutation in a specific population
[3,28,29,30,31]. Most studies reported are based on women with
ovarian cancers, some did not perform haplotype studies, some
cannot rule out the possibility of somatic mutations due to the use
of only tumor samples [32] and others required a larger cohort to
confirm its founder effect [12,33,34]. Further study with a large-
scale Chinese population size is required to evaluate the
association between this founder mutation and breast cancer risk.
The finding from this study suggests that future study will provide
valuable information for genetic counseling and testing in cancer
risk assessment.
Based on our recurrent mutations identified in this study, some
of them such as BRCA1 c.981_982delAT and BRCA2 c.3109C.T
are one of the most common mutations found in Asian countries
such as China, Korea and Singapore [34,35,36]. As expected,
these common mutations are confirmed to be founder mutations.
A number of other mutations were observed at high frequency in
Korea [35], and which were at higher prevalence than those
previously reported as founders. Interestingly, recurrent mutations,
BRCA1 c.5496_5506del11insA, BRCA1 c.390C.A, BRCA2
c.7480C.T and BRCA2 c.3109C.T, are unique mutations that
were not found in either other Asian or even Caucasian
populations according to our database search from BIC and
HGVS. On the other hands, one recurrent mutation BRCA2
c.2808_2811delACAA was frequently observed in other ethnic
populations such as Caucasian, African American, Hispanic and
Australia.
The discovery of this founder mutation may provide a cost-
effective option to rapidly screen a population. Our finding of
complete concordance between conventional sequencing data
and the HRM output in patients DNA suggests that the HRM
technology is ready for use in diagnostic setting. Furthermore,
there are several advantages of using HRM over other mutation
screening methods: (i) Recent reports showed that the sensitivity
and specificity of HRM is better than that of denaturing high-
performance liquid chromatography (DHPLC) which is the
current gold standard of scanning methods [37]; (ii) HRM is
more rapid as the melting analysis is performed in all wells
simultaneously i.e. a closed system whereas DHPLC or other
methods such as fluorescent multiplexed-PCR analysis (FMPA)
involves the post-PCR manipulations and then the sequential
analysis of each sample; (iii) HRM is excellent for heterozygote
detection. Without any labeled probe, HRM can differentiate
between heterozygote and homozygote simultaneously with high
accuracy [38]. In our study these BRCA1 and BRCA2 founder
mutations detectable by conventional DNA sequencing were
also detectable by HRM, giving a high sensitivity for the latter
method. The true sensitivity remains to be determined in a
larger cohort including unselected Chinese women and men.
In conclusion, we conducted an extensive BRCA mutation
analysis in a large Southern Chinese cohort and four founder
mutations were identified. We then rapidly developed HRM
mutation screening assays for those recurrent or founder
mutations. The only BRCA1 confirmed founder mutations
account for 6.9% of all identified BRCA1 mutations, whereas
BRCA2 founder mutations account for 37.5% of all BRCA2
mutations. Our findings indicate that both BRCA1 and BRCA2
Figure 1. Difference plot showing the BRCA1 recurrent or founder mutations relative to the wild type controls. The melting profile of a
wild type (WT) control is chosen as a horizontal base line and the relative differences in the melting of other samples are plotted relative to this
baseline. Each trace represents the amplicon from a different individual’s DNA sample. Melt curves of the BRCA1 founder mutations (green/red) were
plotted against melt curve of the wild type (blue).
doi:10.1371/journal.pone.0043994.g001
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Figure 2. Difference plot showing the three BRCA2 founder mutations relative to the wild type controls. The melting profile of a wild
type (WT) control is chosen as a horizontal base line and the relative differences in the melting of other samples are plotted relative to this baseline.
Each trace represents the amplicon from a different individual’s DNA sample. Melt curves of the BRCA2 founder mutations (green/red) were plotted
against melt curve of the wild type (blue).
doi:10.1371/journal.pone.0043994.g002
BRCA1/2 Founder Mutations in Southern Chinese
PLOS ONE | www.plosone.org 8 September 2012 | Volume 7 | Issue 9 | e43994
mutations account for a substantial proportion of hereditary
breast/ovarian cancer in the Southern Chinese population.
Identification of a founder mutation and knowledge of its
prevalence in the Southern Chinese population provides
important information both to genetic counseling and cancer
risk assessment, as well as to the development of a cost-effective
screening strategy.
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